Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition.
Aclarion's Nociscan platform, powered by augmented intelligence algorithms and biomarkers, represents a breakthrough in chronic pain treatment. With new commercial agreements, UK payer coverage for Nociscan and over $50 million invested in the company's AI platform, Aclarion is making significant strides toward standard-of-care status in the $134 billion U.S. chronic low back pain market. The company’s technology is protected by 40 issued patents and 12 pending applications.
Highlights from the Q&A:Nociscan’s Significant Role in Clinical Trials Ness highlighted Nociscan’s selection in the ongoing LIFEHAB Trial in Norway, a randomized controlled study comparing treatment outcomes for patients with chronic low back pain. The trial aims to evaluate how Nociscan’s magnetic resonance spectroscopy (MRS) biomarkers can assist in determining optimal treatment options. "We are pleased with the progress and look forward to seeing the data further support the use of Nociscan in predicting treatment success," Ness said.
Expansion in Research and Clinical Adoption The discussion touched on Aclarion’s growing momentum in clinical trials and research. "We’re awaiting results from a completed trial in Rome, and two NIH-funded studies in the U.S. examining Nociscan’s role in treating low back pain," Ness shared. Additionally, Aclarion’s CLARITY trial will enroll up to 300 patients across eight sites, aiming to validate Nociscan’s ability to improve surgical outcomes.
KOL Partnerships Driving Payer Coverage Aclarion has also made significant progress in securing payer coverage. "Key Opinion Leader (KOL) surgeons are vital in advocating for Nociscan and driving insurance coverage decisions. We’re working with 10 of the top spine surgeons globally, who see the clinical utility of our technology," Ness explained.
Strategic Growth in the U.S. Looking ahead, Aclarion is expanding its partnerships in key markets across the U.S., targeting the personal injury and worker compensation sectors with its proven Nociscan technology. "We believe the right diagnosis can make a significant difference for workers and insurance providers," Ness stated.
The full interview with Aclarion’s CEO Brent Ness can be found at: PRISM MarketView – Aclarion Q&A : https://prismmarketview.com/disrupting-chronic-pain-treatment-aclarions-nociscan-leads-the-way-in-identifying-painful-spinal-discs/
About Aclarion, Inc.Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives MRS data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
About PRISM MarketView:Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
PRISM MarketView does not provide investment advice.
DisclaimerThis communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients’ securities. See www.pcgadvisory.com/disclosures.
Contact:PRISM MarketViewinfo@prismmarketview.com646-863-6341
Photos accompanying this announcement are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/379e573f-4988-4b42-8d56-83cb74c3dd07https://www.globenewswire.com/NewsRoom/AttachmentNg/e3ca42bd-4fbe-4a22-988d-5d6936e3c91f
Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions
Progressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annually
More than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in identification of painful discs
Technology protected by 23 issued US patents, 17 issued international patents, and 12 pending patent applications
Three of four largest private insurance payers in the UK now covering Nociscan
Partnership with ten prominent KOL surgeons signed on to assist Aclarion in successfully gaining traction and reimbursement throughout the United States
BROOMFIELD, CO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today provided a corporate update. The update reviews the successful achievement of several recent key milestones and provides perspective on the positive implications of those catalysts as the Company continues to establish Nociscan as a standard of care decision support tool for the treatment of patients with chronic low back pain.
“We are excited with the recent positive success we have been awarded as Aclarion has consistently achieved stated catalysts of value creation that fall into a very concise framework proven to bring disruptive technological advancements to standard of care in the healthcare sector,” said Brent Ness, CEO of Aclarion. “We intend to lead a positive diagnostic transformation in spine care through clinical and economic evidence that proves the promising value of Nociscan. The building blocks we have executed over the past two years have recently led to the achievement of our most important catalyst to date which is multiple private insurance companies in the UK electing to pay for Nociscan. Payer coverage is critical to driving Nociscan to standard of care. We are providing this corporate update to share the process involved in achieving this milestone, how that process is being replicated at many sites throughout the U.S., how we are coordinating clinical studies in support of payment, and why increasing payer coverage decisions are critical catalysts for driving the valuation of our company. We are clearly excited not only by our recent successes but even more so for our upcoming near term catalysts.”
The cornerstone of Aclarion’s strategy to drive payer coverage is to partner with Key Opinion Leader (KOL) physicians who see the value of Nociscan in their practice and advocate for insurance coverage so the physician can provide better care to more patients. Aclarion now has a panel of 10 of the top spine surgeon leaders in the world aligned and actively speaking on behalf of the efficacy and clinical utility of adding Nociscan to the evaluation of patients who suffer from chronic low back pain. “These KOLs are participating in the collection of clinical data, they are engaging insurance companies and benefits management entities to advocate for coverage decisions and representing Nociscan as an important technology worthy of societal endorsement,” said Ryan Bond, Chief Strategy Officer of Aclarion. “We believe the quality of a company’s KOL network is a direct reflection of the importance and promise of any new technology and our list of KOLs is more like that of a multibillion-dollar industry leader than an emerging technology disruptor.”
Aclarion’s KOL advocacy strategy applied to the UK has led to great success and is a model of what the Company expects to see replicated with their KOLs in the United States. Physicians in the UK originally set out to evaluate Nociscan technology across 30 patients to determine if the technology was helpful. After comparing Nociscan to invasive discography across only 20 patients, the UK physicians saw the value of Nociscan and converted their trial agreement into a permanent commercial agreement between Aclarion and The London Clinic, a major provider of spine care in London. As part of that conversion, Aclarion was able to secure increased payments. To ensure a large segment of their patients would have unfettered access to Nociscan, the UK KOLs, in conjunction with The London Clinic, then approached the largest private health insurance providers in the UK for payment. Three of the top four payers have now agreed to pay for Nociscan thus far.
Payer coverage decisions like those achieved in the UK represent potentially trajectory changing milestones as they pave the way for broad physician adoption and predictable revenue. Aclarion is now adding sales and marketing resources into London to accelerate this adoption and the potential revenue inherent in these payer coverage decisions. The Company is simultaneously executing this same physician-led strategy throughout the United States through its KOL panel.
To expand access to more KOLs, Aclarion entered into a strategic partnership with ATEC, a major spine implant company with a specific interest in leveraging pre-surgical data to drive better outcomes through its Alpha-Informatics platform. The partnership calls for leveraging ATEC’s extensive physician relationships to expand Aclarion’s KOL advocacy strategy to additional surgeons.
In support of its mission to drive Nociscan to standard of care, Aclarion has executed multiple commercial agreements providing access to Nociscan at multiple MRI scanners in key markets such as New York, New Jersey, Arizona, Colorado, and Michigan. This groundwork will assist in executing the strategic agreement in place with ATEC to evaluate the use of Nociscan with their KOLs. “We believe in the importance of biochemical markers within the treatment paradigm and by partnering with Aclarion, we can progress toward a mutual objective to integrate and advance technologies that improve the predictability and reproducibility of spine patient care,” stated Pat Miles, CEO of ATEC.
The payer world consists of more than standard commercial health insurance providers. In the U.S., personal injury and worker compensation cases make up a large part of the low back pain market and the stakes of securing the right diagnosis are extremely high. In this market in particular, a premium is placed on data that is objectively obtained and can help physicians determine the best treatment options.
By partnering with Justin Kubeck, MD, an orthopedic spine surgeon in New Jersey, Aclarion is expanding into the personal injury and workers compensation market with the same physician-led strategy that is driving positive results in London. Dr. Kubeck explained, “I’ll be leading an effort to educate a discrete population of attorneys and judges who adjudicate PI and WC cases throughout the state on the potential benefits of Nociscan for these high stake cases.”
For KOLs to be most effective in driving payers to cover Nociscan, favorable clinical and economic data from clinical trials is an important requirement. Evidence continues to mount in favor of utilizing Nociscan to determine discogenic pain over the current invasive gold standard of provocative discography and for making treatment decisions when provocative discography data is not available.
The Company was invited to participate in the National Institute of Health’s (NIH) Biomarkers for Evaluating Spine Treatments (BEST) Trial which enrolled over 800 patients at 12 leading academic teaching institutions across the United States, with a subset of 200 undergoing advanced biomarker profiling, which included Nociscan. Results from the trial are anticipated in the near term while the revenue produced from the trial has helped fund Aclarion’s march toward full commercial launch.
The Company has published two peer reviewed journal articles based on the results of a pivotal study conducted by Dr. Matt Gornet showing that clinical outcomes improved and were durable after two years when Nociscan results were concordant with the surgical treatment of a patient versus when surgery did not follow the Nociscan data for identifying painful discs. Bob Eastlack, MD stated, “This is an outcomes result, not just a clinical equivalency to a gold standard diagnostic study. Outcomes are what drive payer coverage decisions.”
To quantify the savings inherent in utilizing Nociscan across the spine surgery population of the United States based on the conclusions of the Gornet study, the Economic Value Analysis of Low back pain (EVAL) analysis was commissioned and executed by the Center for Disruptive Musculoskeletal Innovations (CDMI). The results of EVAL concluded that the use of Nociscan improves outcomes and reduces costs, conservatively saving the US healthcare system nearly half a billion dollars annually and by more than $1,700 per patient. EVAL was presented at the annual International Society for the Advancement of Spine Surgery (ISASS) meeting and at Spine Week in Melbourne Australia. Spine Week is a combination of major spine societies that occurs once every 4 years. EVAL has been submitted for publication in a major spine journal and Aclarion expects to announce that publication shortly.
Building on the clinical success as evidenced by the Gornet study and the favorable economic analysis of EVAL, the Company has launched CLARITY, its flagship clinical study. CLARITY is a prospective, randomized, multi-center trial comparing the outcomes of patients undergoing surgery for chronic discogenic back pain when Nociscan is used in the decision-making process versus when Nociscan is not being used in the decisioning process. Based on the results of the Gornet Trial, Aclarion believes CLARITY will result in compelling data that will rapidly lead to coverage decisions from every major insurance provider in the country and endorsements from all the major spine societies. Nicholas Theodore, MD, FACS, FAANS, Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering is the Principal Investigator for CLARITY.
Additional compelling peer-reviewed data has been published in the International Journal of Spine Surgery that highlights Nociscan as a Gold Standard for noninvasive identification for painful lumbar discs. The LIFEHAB trial continues to pay for the use of Nociscan in the 202-patient study as a key component in their evaluation of surgical vs non-surgical treatment efficacy. The Company expects to announce additional sponsor-supported research studies that generate additional revenue.
Aclarion has expanded its IP position in the MR spectroscopy space and leads on every relevant front as a platform technology that leverages MR spectroscopy and biomarker data for the identification of painful discs. Over the past two years, two key patents have been added. One to expand our IP position when using newer AI analysis techniques to analyze spectroscopy data to identify biomarkers and another to identify bacterial biomarkers associated with pain.
In the months ahead, investors can rely on continued success in adding peer reviewed evidence publications, signing additional commercial agreements, and most importantly, expanding positive payer coverage decisions.
For more information about the BEST Trial, please visit: www.besttrial.org
For information about BACPAC, please visit: https://heal.nih.gov/research/clinical-research/back-pain
For more information about REACH, please visit: www.bacpac-reach.org
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:Kirin M. SmithPCG Advisory, Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG Consulting612.812.7477jodi@sprigconsulting.com
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response
LIFEHAB is a Randomized Controlled Trial in Norway Comparing Lumbar Interbody Fusion Surgery With Multidisciplinary Rehabilitation
LIFEHAB Joins the NIH and Rome in Selecting Nociscan as a Technology to Help Determine Which Discs to Treat and the Technology’s Role in Selecting Optimal Treatment Options
BROOMFIELD, CO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. The randomized controlled trial studying 202 patients with low back pain greater than 1 year in duration will compare treatment outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation. Nociscan was selected for use in the study to help evaluate how magnetic resonance spectroscopy (MRS) biomarkers can identify patient improvement following treatment.
Patient enrollment in LIFEHAB began in the second quarter of 2024. The initial enrolled patients began completing Nociscan exams in the last week of August. Thus far six (6) patients have completed their Nociscan exams.
“We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient,” said Brent Ness, Aclarion CEO. “Although we talk frequently about driving Nociscan to standard of care for clinical use, the research market is proving to be an early adopter of our technology.”
Aclarion is currently awaiting the results of a completed trial in Rome where Nociscan technology was used in a study evaluating regenerative technologies as well as the results of two NIH studies evaluating the role of Nociscan in treating chronic low back pain.
“We see Nociscan moving at an accelerated pace of adoption in the research market and look forward to announcing more partnerships as we continue to drive Nociscan to what we expect to be the gold standard for determining which discs to treat in research protocols on low back pain,” said Ryan Bond, Chief Strategy Officer of Aclarion.
Aclarion believes the results of the LIFEHAB trial, combined with other compelling evidence, marks a key step toward achieving successful reimbursement in a single-payer national health insurance system like Norway.
LIFEHAB is the latest customer-sponsored clinical trial involving Nociscan and the Company looks forward to announcing additional partnerships as Nociscan expands its adoption in the research market.
For more information on the LIFEHAB Trial:
https://classic.clinicaltrials.gov/ct2/show/NCT06169488
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects, and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:Kirin M. SmithPCG Advisory, Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG Consulting612.812.7477jodi@sprigconsulting.com
NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index, which highlights companies at the forefront of innovation and market disruption in the medtech sector. Aclarion’s innovative AI-driven diagnostic solutions for chronic low back pain position the company as a standout in the evolving medical devices sector.
The U.S. medical devices market is projected to grow significantly, reaching an estimated value of nearly $315 billion by 2032. This expansion is driven by increasing R&D investments and a robust pipeline of innovations, including Aclarion’s NOCISCAN technology, which offers the first noninvasive, AI-supported diagnostic tool for identifying painful discs in patients suffering from chronic low back pain.
Lower back pain is one of the largest healthcare expenditures in the United States, with the market for lumbar spine diagnostics and treatment estimated at $40 billion annually and overall costs reaching up to $134.5 billion. Aclarion’s NOCISCAN technology addresses this growing need by offering a noninvasive diagnostic alternative.
Aclarion Standouts:
For more information on Aclarion and the PRISM Emerging Medical Devices Index, visit prismmarketview.com.
About Aclarion, Inc.Aclarion is a healthcare technology company that leverages magnetic resonance spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with NOCISCAN, the first, evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, NOCISCAN receives magnetic resonance spectroscopy data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, NOCISCAN provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
About PRISM MarketView Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
PRISM MarketView does not provide investment advice.
Disclaimer: This communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients’ securities. See www.pcgadvisory.com/disclosures.
Contact: PRISM MarketView info@prismmarketview.com 646-863-6341
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9a4c45b4-63ec-4049-a7b8-16369cff9c9a
Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population
Average Settlement in New Jersey for Personal Injury Claims Involving the Neck and Back is $918,967
Work-related Accidents Which Cause Neck and Back Injuries Have a National Average Settlement of $148,750
BROOMFIELD, CO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a program to develop a statewide network of providers in New Jersey to utilize Nociscan throughout the personal injury and workers compensation population.
Justin Kubeck, MD, an orthopedic surgeon and founder of Ocean Pain and Spine in Toms River, NJ will initiate a focused effort to improve the objective evaluation of chronic low back pain patients throughout the complex personal injury and workers compensation system that aims to provide the right treatments and financial compensation to patients suffering from injury.
“The personal injury and workers compensation ecosystem involves a discrete number of judges and lawyers who work to adjudicate claims leveraging the expertise of physicians dedicated to understanding this unique segment of the healthcare system. The nature of these claims mandates an objective and definitive diagnosis, knowing that the diagnosis may well be challenged in a legal setting. The use of Nociscan can be a powerful objective measurement tool to provide a strong case for supporting an appropriate treatment pathway,” said Dr. Kubeck. “Over the next several months, I will be working to educate the network of judges and lawyers who determine the appropriateness of recommended treatments on the value Nociscan brings to my patients and the value I think it can bring to improving the workers compensation and personal injury evaluation process.”
Workers compensation and personal injury claims involving the neck and back have significant financial implications for workers, employers, and insurance companies. Although there are many factors that go into the final settlement or jury verdict associated with these cases, whether surgical intervention is required or not is often a clear delineating point for the size of the settlement. Because Nociscan directly measures biomarkers in the lumbar disc correlated to pain and structural integrity, Nociscan is positioned to provide important objective data that providers can use as they formulate and defend their recommended treatment plan.
Ryan Bond, Chief Strategy Officer of Aclarion, commented, “Once established in New Jersey, we will target other markets throughout the United States to replicate the success of the NJ market. We believe this population is the perfect fit for the use of advanced biomarker identifications correlated to pain and available exclusively through the Nociscan platform.”
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:Kirin M. SmithPCG Advisory, Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG Consulting612.812.7477jodi@sprigconsulting.com
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.